Steven Kalkanis, MD
Affiliations: | 2014- | Neurosurgery | Henry Ford Health System |
Google:
"Steven Kalkanis"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zakaria HM, Wilkinson BM, Pennington Z, et al. (2020) Sarcopenia as a Prognostic Factor for 90-Day and Overall Mortality in Patients Undergoing Spine Surgery for Metastatic Tumors: A Multicenter Retrospective Cohort Study. Neurosurgery |
| Wells M, Asmaro KP, Sabedot TS, et al. (2020) OR32-03 Serum Cell-Free Methylation-Based Signatures Distinguishes Pituitary Tumors According to Functional Status and from Other Neoplasia: A Liquid Biopsy Approach Journal of the Endocrine Society. 4 |
| Wells M, Asmaro K, Rock J, et al. (2020) Abstract A11: Serum cell-free DNA methylome-based signatures distinguish pituitary tumor from other neoplasias and by clinicopathologic features Clinical Cancer Research. 26 |
| Sabedot T, Malta T, Snyder J, et al. (2020) Abstract A10: Glioma cell-free DNA methylation marker for diagnosis and monitoring Clinical Cancer Research. 26 |
| Sabedot TS, Malta TM, She R, et al. (2020) Abstract 781: Methylation-based liquid biopsy of meningioma primary and recurrent samples Cancer Research. 80: 781-781 |
| de Souza CF, Sabedot TS, Malta TM, et al. (2018) A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. Cell Reports. 23: 637-651 |
| Cloughesy TF, Landolfi J, Vogelbaum M, et al. (2018) Abstract A085: Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment Molecular Cancer Therapeutics. 17 |
| Sabedot T, deCarvalho A, Poisson L, et al. (2018) GENE-13. GENOMIC FUNCTIONAL ENHANCERS DEFINE POTENTIAL TUMORIGENESIS OF G-CIMP-LOW (IDH-MUTANT ASTROCYTOMA) TUMORS INDEPENDENT OF PROMOTER METHYLATION Neuro-Oncology. 20: vi105-vi105 |
| Mosella M, Malta T, Sabedot T, et al. (2018) GENE-07. GENOMIC ENHANCER METHYLATION IS ASSOCIATED WITH BIOLOGICAL AND CLINICAL FEATURES IN PITUITARY TUMORS Neuro-Oncology. 20: vi104-vi104 |
| Accomando W, Cloughesy T, Kalkanis S, et al. (2018) ATIM-26. IMMUNOLOGIC TRENDS ASSOCIATED WITH PATIENT OUTCOMES IN A PHASE 1 CLINICAL TRIAL OF TOCA 511 AND TOCA FC IN RECURRENT HIGH GRADE GLIOMA Neuro-Oncology. 20: vi6-vi7 |